GNAS and hepatocellular carcinoma: The stratification analysis indicated that autoantibody to GNAS in early-stage HCC patients (sensitivity of 43.4% and AUC of 0.655) presented better performance than that in late-stage HCC patients (sensitivity of 37.2% and AUC of 0.573) although the difference was not significant (Figure 2B,E).